Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50–59 years at increased risk of severe RSV disease and those aged ≥60 years

Key Points

• This research aims to evaluate the cost-effectiveness of the RSVPreF3 vaccine in adults at risk for severe RSV disease.
• Conducted a cost-effectiveness analysis in adults aged 50-59 and those 60 and older.
• Included health outcomes related to RSV vaccination in the analysis.
• Assessed economic factors such as vaccine cost and potential savings from reduced disease burden.
• The RSVPreF3 vaccine is likely to offer substantial health benefits in the assessed age groups.
• Implementation of the vaccine is expected to be cost-effective in reducing RSV-related healthcare costs.